Alvotech Announces Increase in Number of Own Shares

Alvotech (NASDAQ: ALVO) increased share capital by USD 125,000 through issuance of 12,500,000 ordinary shares at USD 5.20 per share to its subsidiary Alvotech Manco ehf.

Rhea-AI Summary

Alvotech (NASDAQ: ALVO) increased share capital by USD 125,000 through issuance of 12,500,000 ordinary shares at USD 5.20 per share to its subsidiary Alvotech Manco ehf.

The subsidiary's holding rises to 16,254,005 shares (4.7%); total issued shares increased from 334,038,147 to 346,538,147. Outstanding shares remain 330,284,142. The increase supports settlement of a prior stock lending facility and the company's obligations for warrants, convertibles, and employee programs.

Argus Feb 11 session

-6.73% close to close Open Argus

Details

News Market Reaction – ALVO

On Feb 11, the day this news came out, ALVO closed 6.73% below the previous close.

Data tracked by StockTitan Argus for the Feb 11 session.

Market Context

On Feb 11, the day this news came out, the stock closed 6.7% below the previous close. A negative re...

Analysis

On Feb 11, the day this news came out, the stock closed 6.7% below the previous close. A negative reaction despite the unchanged outstanding share count of 330,284,142 would fit a pattern where the market sometimes responds cautiously to structural or financing-related news. Recent history shows mixed price responses to otherwise constructive updates. Concerns might focus on potential future use of treasury shares for financial obligations, even though this transaction primarily restores the company’s treasury position.

Key Figures

Share capital increase: USD 125,000 New shares issued: 12,500,000 shares Subscription price: USD 5.2 per share +4 more

Share capital increase

USD 125,000

Increase in company share capital via new ordinary shares

New shares issued

12,500,000 shares

Ordinary shares subscribed by subsidiary

Subscription price

USD 5.2 per share

Price paid by subsidiary for newly issued shares

Subsidiary holdings

16,254,005 shares

Treasury shares held, equal to 4.7% of issued shares

Total issued shares

346,538,147 shares

Increased from 334,038,147 after capital change

Outstanding shares

330,284,142 shares

Outstanding share count unchanged after transaction

Treasury share stake

4.7% of issued shares

Proportion of issued shares held by subsidiary as treasury

Historical Context

5 past events · Latest: Feb 05

5 events

1. Feb 05

   Clinical study results

   24h Move

   -2.0%

   Pivotal PK study for Entyvio biosimilar met all primary endpoints.

2. Feb 02

   Commercial agreements

   24h Move

   -0.9%

   Supply and commercialization deals with Sandoz in Canada and ANZ.

3. Jan 29

   Patent settlement

   24h Move

   +2.5%

   Global licensing and settlement for Eylea biosimilar enabling market entry.

4. Jan 07

   Insider filing correction

   24h Move

   +1.5%

   Corrected disclosure of closely associated person share transactions.

5. Jan 06

   Insider transactions

   24h Move

   -6.5%

   Disclosure of large share purchases by ATP Holdings ehf.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

treasury shares, convertible bonds, warrants

3 terms

treasury shares financial

"The shares held by the subsidiary are treated as treasury shares without voting rights"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

convertible bonds financial

"stock lending facility to the buyers of Convertible Bonds issued by the Company"

A convertible bond is a loan a company issues that pays regular interest and can be exchanged for a fixed number of the company’s shares under specified terms. It matters to investors because it combines the steady income and lower downside risk of a bond with the upside potential of owning stock—like holding a ticket that can be cashed for equity if the share price rises—affecting returns, risk, and shareholder dilution.

warrants financial

"commitments related to various financial obligations, including warrants, convertible financial instruments"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REYKJAVIK, ICELAND (February 11, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and twenty-five thousand (USD 125,000) by issuing twelve million and five-hundred thousand (12,500,000) ordinary shares. The Company’s subsidiary, Alvotech Manco ehf. (the “subsidiary”), has subscribed to all of the newly issued shares for a price of USD 5.2 per share. The shares held by the subsidiary are treated as treasury shares without voting rights or dividend entitlement.

Following the above-mentioned transaction, the subsidiary will hold 16,254,005 shares in the Company, or 4.7% of issued shares, and the number of total issued shares has increased from 334,038,147 to 346,538,147 shares. The number of outstanding shares, consisting of all shares not held as treasury shares by the subsidiary, is unchanged at 330,284,142 shares.

On December 17, 2025, the Company announced that it had provided a stock lending facility to the buyers of Convertible Bonds issued by the Company, for the purpose of facilitating the Convertible Bond investors' hedging activities. The share capital increase is intended to meet the reduction in the number of treasury shares resulting from settlement of the above-mentioned lending of ordinary shares, allowing the Company to continue holding a sufficient number of shares to fulfill the Company’s commitments related to various financial obligations, including warrants, convertible financial instruments, and share-based employee compensation.

CONTACT INFORMATION – INVESTOR RELATIONS
Balaji Prasad, Chief Strategy Officer
Patrik Ling, VP Investor Relations Scandinavia (SE)
Benedikt Stefansson, VP Investor Relations and Global Communications (IS)
alvotech.ir@alvotech.com

About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars, to Humira® (adalimumab), Stelara® (ustekinumab), Eylea® (aflibercept), Simponi® (golimumab) and Prolia®/Xgeva® (denosumab) are already approved and marketed in global markets. Alvotech’s current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, respiratory disease, hematological disorders and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit www.alvotech.com.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Alvotech (ALVO) increase its share capital on February 11, 2026?

The company increased share capital to restore treasury share levels needed to meet obligations. According to the company, the issuance supports settlement of a prior stock lending facility and ensures availability for warrants, convertibles, and employee compensation.

How many shares did Alvotech (ALVO) issue and at what price on February 11, 2026?

Alvotech issued 12,500,000 ordinary shares at USD 5.20 per share. According to the company, this raised share capital by USD 125,000 and the shares were subscribed by its subsidiary Alvotech Manco ehf.

What is the effect on Alvotech's (ALVO) total issued and outstanding shares after the increase?

Total issued shares rose to 346,538,147, while outstanding shares remain 330,284,142. According to the company, the subsidiary holds treasury shares and voting/dividend rights are not applicable to those treasury shares.

How much of Alvotech (ALVO) will the subsidiary hold after the transaction and what percent does it represent?

The subsidiary will hold 16,254,005 shares, representing 4.7% of issued shares. According to the company, these shares are treated as treasury shares without voting rights or dividend entitlement.

Does the share issuance dilute Alvotech (ALVO) outstanding shares available to investors?

Outstanding shares remained unchanged at 330,284,142, so investor-held outstanding shares were not increased. According to the company, the issuance was to replenish treasury shares after stock lending settlements rather than expand publicly tradable shares.